Cat. No.: HY-N1073

Wighteone

(Synonyms: 6-Isopentenylgenistein; Erythrinin B)

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Wighteone (6-Isopentenylgenistein; Erythrinin B) is a prenylated isoflavone that acts as a HSP90/EGFR^L858R/T790M inhibitor and antifungal agent. Wighteone reduces the expression level of HSP90, blocks EGF-induced phosphorylation of EGFR, and thereby inhibits the downstream ERK and AKT signaling pathways. Wighteone induces cell cycle redistribution, inhibits proliferation and triggers apoptosis in cancer cells. Wighteone can be isolated from Erythrina suberosa, and can also be induced to synthesize in Lotus japonicus under specific conditions. Wighteone can be used to study HER2-positive breast cancer, leukemia, non-small cell lung cancer with EGFR^L858R/T790M mutation, and fungal infections.

For research use only. We do not sell to patients.

Purity: 98.71%
CAS No.: 51225-30-0
Formula: C₂₀H₁₈O₅
Molecular Weight:338.35

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Wighteone Chemical Structure

CAS No.: 51225-30-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

EGFR^L858R/T790M

HSP90

All EGFR Isoforms :

All HSP Isoforms :

All ERK Isoforms :

All Akt Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
HSC-2	CC₅₀	0.12 mM Compound: 22, wighteone	Cytotoxicity against human HSC2 cells Cytotoxicity against human HSC2 cells	[PMID: 11170668]
U-937	IC₅₀	28 μM Compound: 14, erythrinin B	Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	32 μM Compound: 14, erythrinin B	Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	35 μM Compound: 14, erythrinin B	Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay	[PMID: 17158054]

In Vitro

Wighteone (8.0 mM; 48 h) inhibits the proliferation of HER2-positive MCF-7 breast cancer cells with an inhibition rate of 29.17%^[1]; Wighteone also inhibits the proliferation of Ba/F3 EGFR^L858R/T790M cells and H1975 cells, with IC₅₀ values of 1.88 μM and 5.70 μM, respectively^[2].
Wighteone (0.5-10.0 mM; 48 h) induces apoptosis in HER2-positive MCF-7 breast cancer cells, with a maximum apoptosis rate of 14.98% observed at the concentration of 10.0 mM^[1].
Wighteone (0.5-10.0 mM; 24-48 h) downregulates the expression of HSP90 protein in HER2-positive MCF-7 breast cancer cells in vitro in a dose- and time-dependent manner^[1].
Wighteone (2.5-10 μM; 24 h) reduces the clonogenic potential of NCI-H1975 cells in a dose-dependent manner^[2].
Wighteone (2.5-10 μM; 24 h treatment for flow cytometry, 16 h treatment for WB) induces S-phase cell cycle arrest in NCI-H1975 cells by regulating the expression of key cell cycle regulatory proteins CDK2, cyclin A and cyclin E, and inhibits EGF-induced activation of the EGFR signaling pathway, including its downstream molecules Erk and AKT^[2].
Wighteone (2.5-10 μM; 24 h treatment for flow cytometry, 16 h treatment for WB) induces apoptosis in NCI-H1975 cells in a dose-dependent manner by activating the caspase-dependent pathway and regulating pro-apoptotic and anti-apoptotic proteins^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

HER2-positive MCF-7 breast cancer cells
Concentration:

0.5 mM, 5.0 mM, 10.0 mM
Incubation Time:

24 h, 48 h
Result:

Significantly reduced HSP90 protein expression compared with the control group, with the inhibitory effect enhanced at higher concentrations.
Showed significantly lower HSP90 expression at 48 h than at 24 h in treated cells.

Cell Cycle Analysis^[2]

Cell Line:

NCI-H1975 human NSCLC cells (EGFR L858R/T790M mutant)
Concentration:

2.5-10 μM (flow cytometry); 2.5-10 μM (Western blot, following 5 min EGF pre-stimulation)
Incubation Time:

24 h (flow cytometry); 16 h (Western blot, following 5 min EGF pre-stimulation)
Result:

Dose-dependently increased the proportion of cells in the S phase.
Significantly decreased CDK2 and cyclin A protein levels and increased cyclin E protein levels in a concentration-dependent manner, compared to EGF alone.

Apoptosis Analysis^[1]

Cell Line:

HER2-positive MCF-7 breast cancer cells
Concentration:

0.5 mM, 5.0 mM, 10.0 mM
Incubation Time:

48 h
Result:

Induced apoptosis in cells after 48 h of treatment, with apoptotic rates of 4.22% (0.5 mM), 6.54% (5.0 mM), and 14.98% (10.0 mM).
Showed a significantly higher apoptotic rate in the 10.0 mM group compared with the control group and the 0.5 mM group.

Apoptosis Analysis^[2]

Cell Line:

NCI-H1975 human NSCLC cells (EGFR L858R/T790M mutant)
Concentration:

2.5-10 μM
Incubation Time:

24 h for flow cytometry; 16 h for Western blot, following 5 min EGF pre-stimulation
Result:

Dose-dependently increased the rate of apoptotic cells.
Significantly increased protein levels of cleaved-caspase3, cleaved-caspase9, cleaved-PARP1, and Bax, and decreased Bcl-2 protein levels, compared to EGF alone.

Chemical Information

CAS No. 51225-30-0
Appearance Solid
Molecular Weight 338.35
Formula C₂₀H₁₈O₅
Color Off-white to light yellow
SMILES

OC1=C(C2=O)C(OC=C2C3=CC=C(C=C3)O)=CC(O)=C1C/C=C(C)/C
Synonyms

6-Isopentenylgenistein; Erythrinin B
Structure Classification
- Flavonoids
- Isoflavones
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All

Sort by:

Journal Impact Factor

Microchem J

2025 Sep 13;218:115323.
J Sep Sci

A Monoclonal Antibody-based Lateral Flow Immunochromatographic Assay for Rapid Detection of Derrisisoflavone A in Derris scandens (Roxb.) Benth. [Abstract]

2026 May;49(5):e70428. PMID: 42068121

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (295.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9555 mL

14.7776 mL

29.5552 mL

5 mM

0.5911 mL

2.9555 mL

5.9110 mL

10 mM

0.2956 mL

1.4778 mL

2.9555 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (481 KB)
- English - EN (481 KB)
- Français - FR (481 KB)
- Deutsch - DE (481 KB)
- Norwegian - NO (481 KB)
- Español - ES (481 KB)
- Swedish - SV (481 KB)
- Italian - IT (481 KB)
- Korean - KR (481 KB)
- Portuguese - PT (481 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Cao ZW, et al. HSP90 expression and its association with wighteone metabolite response in HER2-positive breast cancer cells. Oncol Lett. 2016;11(6):3719-3722. [Content Brief]

[2]. Sun P, et al. Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer. J Cancer. 2021;12(13):3900-3908. Published 2021 May 5. [Content Brief]

[3]. Liu J, et al. Genistein-Specific G6DT Gene for the Inducible Production of Wighteone in Lotus japonicus. Plant Cell Physiol. 2018;59(1):128-141. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9555 mL	14.7776 mL	29.5552 mL	73.8880 mL
	5 mM	0.5911 mL	2.9555 mL	5.9110 mL	14.7776 mL
	10 mM	0.2956 mL	1.4778 mL	2.9555 mL	7.3888 mL
	15 mM	0.1970 mL	0.9852 mL	1.9703 mL	4.9259 mL
	20 mM	0.1478 mL	0.7389 mL	1.4778 mL	3.6944 mL
	25 mM	0.1182 mL	0.5911 mL	1.1822 mL	2.9555 mL
	30 mM	0.0985 mL	0.4926 mL	0.9852 mL	2.4629 mL
	40 mM	0.0739 mL	0.3694 mL	0.7389 mL	1.8472 mL
	50 mM	0.0591 mL	0.2956 mL	0.5911 mL	1.4778 mL
	60 mM	0.0493 mL	0.2463 mL	0.4926 mL	1.2315 mL
	80 mM	0.0369 mL	0.1847 mL	0.3694 mL	0.9236 mL
	100 mM	0.0296 mL	0.1478 mL	0.2956 mL	0.7389 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Wighteone

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Endoplasmic Reticulum Stress Compound Library

Medicine Food Homology Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Hepatitis C Virus Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cytokine Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Extracellular Vesicles (EVs) Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Wighteone